Biotech News

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Anebulo Pharmaceuticals (ANEB)Anebulo Pharmaceuticals2026-01-27 14:00 ESTCompany update

ANEB (ANEB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is aneb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Anebulo Pharmaceuticals

Cannabis-Toxicity Antidote Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC. Selonabant Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral...

Recent company news

ANEBAnebulo Pharmaceuticals2026-02-12 21:15 EST

Stock data

Close: 0.33 USD
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Related news

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Anebulo Pharmaceuticals

Recent company news

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

Stock data